{"id":"W4405375144","doi":"10.1016/j.iotech.2024.100750","title":"121MO Anti-IL-8 (BMS-986253) in combination with nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with advanced melanoma: Final analysis from the randomized part 2 of the phase I/II CA027-002 study","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; PharmaMar; European Society for Medical Oncology","keywords":"Nivolumab; Ipilimumab; Medicine; Metastatic melanoma; Internal medicine; Melanoma; Oncology; Cancer research; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000931239,0.0003755923,0.001661643,0.0009428537,0.0001742488,0.00001788176,0.0005633139,0.0004105035,0.0001457919],"category_scores_gemma":[0.0001428035,0.0002049609,0.0002466351,0.003740381,0.00131304,0.0001234623,0.0001875949,0.0008224278,0.000003645033],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008154055,"about_ca_system_score_gemma":0.0006102847,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001652289,"about_ca_topic_score_gemma":0.006222238,"domain_scores_codex":[0.9969364,0.0005634896,0.0009990287,0.0006499258,0.0003957578,0.0004553576],"domain_scores_gemma":[0.9977614,0.0005837354,0.0004342826,0.00101209,0.0001805073,0.00002801734],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5114074,0.01322886,0.3235366,0.00007118074,0.01086411,0.0003586503,0.007967453,0.0002041764,0.005384441,0.0003339698,0.0002975323,0.1263456],"study_design_scores_gemma":[0.8140933,0.02113009,0.1456607,0.0005452395,0.003632281,0.00005179162,0.006122132,0.001365196,0.002845817,0.0002662761,0.003812307,0.0004749108],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896531,0.003045817,0.0000791643,0.003260729,0.0003952253,0.003187416,0.00005399101,0.0001197138,0.0002048525],"genre_scores_gemma":[0.9985675,0.0002742041,0.0001344923,0.0001455838,0.00001990128,0.0005736843,0.00008330806,0.00003792135,0.0001633964],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3026859,"threshold_uncertainty_score":0.8358063,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008657859952414042,"score_gpt":0.2774406519264998,"score_spread":0.2687827919740858,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}